nach oben

Erschienen in:

04.08.2018 | Clinical Study

Neurocognitive evaluation of brain metastases patients treated with post-resection stereotactic radiosurgery: a prospective single arm clinical trial

verfasst von: Assaf Berger, Ido Strauss, Shlomit Ben Moshe, Benjamin W. Corn, Dror Limon, Nathan Shtraus, Tal Shahar, Andrew A. Kanner

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Post-operative radiation therapy for brain metastases (BM) has become standard treatment. Concerns regarding the deleterious cognitive effects of Whole Brain Radiation Therapy spurred a trend to use focal therapies such as stereotactic radiosurgery (SRS). The purpose of this study was to prospectively evaluate the neuropsychological effects following post-resection SRS treatment since limited data exist in this context.

Methods

We conducted a prospective single arm cohort study of patients with 1–2 BM, who underwent resection of a single BM between May 2015 to December 2016. Patients were evaluated for cognitive functions (NeuroTrax computerized neuropsychological battery; Modiin, Israel) and quality of life (QOL; QLQ-30, QLQ-BN20) before and 3 months following post-resection SRS.

Results

Twelve out of 14 patients completed pre- and post-SRS neurocognitive assessments. Overall, we did not detect significant neurocognitive or QOL changes 3 months following SRS. In a subgroup analysis among patients younger than 60 years, median global cognitive score increased from a pre-treatment score of 88 (72–102) to 95 (79–108), 3 months following SRS treatment, p = 0.042; Wilcoxon paired non-parametric test. Immediate verbal memory and executive functions scores increased from 86 (72–98) to 98 (92–112) and 86 (60–101) to 100 (80–126), respectively, p = 0.043. No significant cognitive changes were discovered among patients at the age of 60 or older.

Conclusions

Post-resection radiosurgery has a safe neuro-cognitive profile and is associated with preservation of nearly all quality of life parameters. Patients younger than 60 years benefit most and may even regain some cognitive functions within a few months after treatment.

Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG II, Deming R, Burri SH, Menard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316:401–409. https://doi.org/10.1001/jama.2016.9839 CrossRefPubMedPubMedCentral

Amsbaugh MJ, Boling W, Woo S (2015) Tumor bed radiosurgery: an emerging treatment for brain metastases. J Neurooncol 123:197–203. https://doi.org/10.1007/s11060-015-1789-y CrossRefPubMed

Roberge D, Parney I, Brown PD (2012) Radiosurgery to the postoperative surgical cavity: who needs evidence? Int J Radiat Oncol Biol Phys 83:486–493. https://doi.org/10.1016/j.ijrobp.2011.09.032 CrossRefPubMed

Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485–1489CrossRefPubMed

Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29:134–141. https://doi.org/10.1200/jco.2010.30.1655 CrossRefPubMed

Pinkham MB, Sanghera P, Wall GK, Dawson BD, Whitfield GA (2015) Neurocognitive effects following cranial irradiation for brain metastases. Clin Oncol 27:630–639. https://doi.org/10.1016/j.clon.2015.06.005 CrossRef

Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y, Chan TA, Lymberis SC, Narayana A, Tabar V, Gutin PH, Ballangrud A, Lis E, Beal K (2014) A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 88:130–136. https://doi.org/10.1016/j.ijrobp.2013.09.051 CrossRefPubMedPubMedCentral

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491. https://doi.org/10.1001/jama.295.21.2483 CrossRefPubMed

Pessina F, Navarria P, Cozzi L, Ascolese AM, Maggi G, Riva M, Masci G, D’Agostino G, Finocchiaro G, Santoro A, Bello L, Scorsetti M (2016) Outcome evaluation of oligometastatic patients treated with surgical resection followed by hypofractionated stereotactic radiosurgery (HSRS) on the tumor bed, for single, large brain metastases. PLoS ONE 11:e0157869. https://doi.org/10.1371/journal.pone.0157869 CrossRefPubMedPubMedCentral

10.

Chao ST, De Salles A, Hayashi M, Levivier M, Ma L, Martinez R, Paddick I, Regis J, Ryu S, Slotman BJ, Sahgal A (2017) Stereotactic radiosurgery in the management of limited (1–4) brain metasteses: Systematic review and international stereotactic radiosurgery society practice guideline. Neurosurgery. https://doi.org/10.1093/neuros/nyx522 CrossRefPubMed

11.

Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037–1044. https://doi.org/10.1016/s1470-2045(09)70263-3 CrossRefPubMed

12.

Strauss I, Corn BW, Krishna V, Shahar T, Matceyevsky D, Gez E, Shtraus N, Ram Z, Kanner AA (2015) Patterns of failure after stereotactic radiosurgery of the resection cavity following surgical removal of brain metastases. World Neurosurg 84:1825–1831. https://doi.org/10.1016/j.wneu.2015.07.073 CrossRefPubMed

13.

Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG II, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, Roberge D (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049–1060. https://doi.org/10.1016/s1470-2045(17)30441-2 CrossRefPubMedPubMedCentral

14.

Minniti G, Soltys SG, Halasz LM, Breneman JC, Chan M, Laack NN, Kirkpatrick JP (2018) Stereotactic radiosurgery for resected brain metastases: new evidence supports a practice shift, but questions remain. Int J Radiat Oncol Biol Phys 100:535–538. https://doi.org/10.1016/j.ijrobp.2017.08.024 CrossRefPubMed

15.

Lamba N, Muskens IS, DiRisio AC, Meijer L, Briceno V, Edrees H, Aslam B, Minhas S, Verhoeff JJC, Kleynen CE, Smith TR, Mekary RA, Broekman ML (2017) Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol 12:106. https://doi.org/10.1186/s13014-017-0840-x CrossRefPubMedPubMedCentral

16.

Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa K, Nakagawa K, Kobashi G, Shirato H (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388–1395. https://doi.org/10.1016/j.ijrobp.2007.03.048 CrossRefPubMed

17.

Dwolatzky T, Whitehead V, Doniger GM, Simon ES, Schweiger A, Jaffe D, Chertkow H (2003) Validity of a novel computerized cognitive battery for mild cognitive impairment. BMC Geriatr. https://doi.org/10.1186/1471-2318-3-4 CrossRefPubMedPubMedCentral

18.

Hausdorff JM, Doniger GM, Springer S, Yogev G, Simon ES, Giladi N (2006) A common cognitive profile in elderly fallers and in patients with Parkinson’s disease: the prominence of impaired executive function and attention. Exp Aging Res 32:411–429. https://doi.org/10.1080/03610730600875817 CrossRefPubMedPubMedCentral

19.

Springer S, Giladi N, Peretz C, Yogev G, Simon ES, Hausdorff JM (2006) Dual-tasking effects on gait variability: the role of aging, falls, and executive function. Mov Disord 21:950–957. https://doi.org/10.1002/mds.20848 CrossRefPubMed

20.

Schweiger ADG, Dwolatzky T, Jaffe D, Simon ES (2003) Reliability of a novel computerized neuropsychological battery for mild cognitive impairment. Acta Neuropsychol 1:407–413CrossRef

21.

Kave G, Knafo-Noam A (2015) Lifespan development of phonemic and semantic fluency: universal increase, differential decrease. J Clin Exp Neuropsychol 37:751–763. https://doi.org/10.1080/13803395.2015.1065958 CrossRefPubMed

22.

Leung A, Lien K, Zeng L, Nguyen J, Caissie A, Culleton S, Holden L, Chow E (2011) The EORTC QLQ-BN20 for assessment of quality of life in patients receiving treatment or prophylaxis for brain metastases: a literature review. Expert Rev Pharmacoecon Outcomes Res 11:693–700. https://doi.org/10.1586/erp.11.66 CrossRefPubMed

23.

Caissie A, Nguyen J, Chen E, Zhang L, Sahgal A, Clemons M, Kerba M, Arnalot PF, Danjoux C, Tsao M, Barnes E, Holden L, Danielson B, Chow E (2012) Quality of life in patients with brain metastases using the EORTC QLQ-BN20 + 2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys 83:1238–1245. https://doi.org/10.1016/j.ijrobp.2011.09.025 CrossRefPubMed

24.

Soliman H, Das S, Larson DA, Sahgal A (2016) Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 7:12318–12330. https://doi.org/10.18632/oncotarget.7131 CrossRefPubMedPubMedCentral

25.

Foreman PM, Jackson BE, Singh KP, Romeo AK, Guthrie BL, Fisher WS, Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB (2017) Postoperative radiosurgery for the treatment of metastatic brain tumor: evaluation of local failure and leptomeningeal disease. J Clin Neurosci. https://doi.org/10.1016/j.jocn.2017.12.009 CrossRefPubMedPubMedCentral

26.

Caine C, Deshmukh S, Gondi V, Mehta M, Tome W, Corn BW, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Raben A, Shi W, Wendland M, Kachnic L (2016) CogState computerized memory tests in patients with brain metastases: secondary endpoint results of NRG oncology RTOG 0933. J Neurooncol 126:327–336. https://doi.org/10.1007/s11060-015-1971-2 CrossRefPubMed

27.

Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32:3810–3816. https://doi.org/10.1200/jco.2014.57.2909 CrossRefPubMedPubMedCentral

28.

Martins R, Joanette Y, Monchi O (2015) The implications of age-related neurofunctional compensatory mechanisms in executive function and language processing including the new temporal hypothesis for compensation. Front Hum Neurosci 9:221. https://doi.org/10.3389/fnhum.2015.00221 CrossRefPubMedPubMedCentral

29.

Chen L, Shen C, Redmond KJ, Page BR, Kummerlowe M, McNutt T, Bettegowda C, Rigamonti D, Lim M, Kleinberg L (2017) Use of stereotactic radiosurgery in elderly and very elderly patients with brain metastases to limit toxicity associated with whole brain radiation therapy. Int J Radiat Oncol Biol Phys 98:939–947. https://doi.org/10.1016/j.ijrobp.2017.02.031 CrossRef

30.

Zeng KL, Raman S, Sahgal A, Soliman H, Tsao M, Wendzicki C, Chow E, Lo SS (2017) Patient preference for stereotactic radiosurgery plus or minus whole brain radiotherapy for the treatment of brain metastases. Ann Palliat Med 6:S155–Ss160. https://doi.org/10.21037/apm.2017.06.11 CrossRefPubMed

Titel: Neurocognitive evaluation of brain metastases patients treated with post-resection stereotactic radiosurgery: a prospective single arm clinical trial
verfasst von: Assaf Berger
Ido Strauss
Shlomit Ben Moshe
Benjamin W. Corn
Dror Limon
Nathan Shtraus
Tal Shahar
Andrew A. Kanner
Publikationsdatum: 04.08.2018
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2954-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status

Granular cell tumor of the infundibulum: a systematic review of MR-radiography, pathology, and clinical findings

Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus

Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up